ANZGOG attends Asia Pacific Gynecologic Oncology Trials Group (APGOT) meeting in Singapore.
ANZGOG leader Prof Michael Friedlander AM and CEO Alison Evans were in Singapore in November, discussing an Asia Pacific collaboration for clinical trials with clinical leaders from Japan, Singapore and Korea.
Prof Michael Friedlander AM said “the meeting was a very productive and will strengthen ANZGOG and our trial portfolio.”
The Asia Pacific Gynaecologic Oncology Trials Group (APGOT) has been founded with Dr David Tan of Singapore, inaugural Chair, and Byoung Kim of South Korea, Chair-elect. Noriko Fujiwara of Japan is the Operations Chair. The group was formed to focus on collaborative studies in gynaecological cancer within the Asia Pacific region, strengthening capabilities and ensuring a greater range of trials available for women.
“The APGOT collaboration will enable practice changing trials to be carried out in the Asia Pacific region.” said Alison Evans.
APGOT will focus on Phase II Clinical Trials and studies that can be co-developed with industry funders. Strong links are to be forged with ENGOT in Europe. Members can expect early access to new treatments for some of the more difficult to treat cancer subtypes through these clinical trials.
APGOT meetings will be held bi-annually with the next meeting taking place at GCIG/ASCO in Chicago in May/June 2020.